DDInter350 DDInter1144
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Melphalan
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Melphalan
Chlorambucil {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Melphalan
Chlorambucil {u} (Compound) causes {v} (Side Effect) Interstitial lung disease
Interstitial lung disease {u} (Side Effect) is caused by {v} (Compound) Melphalan
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) resembles {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Melphalan
Chlorambucil {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) resembles {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Melphalan
Chlorambucil {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Melphalan
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Chlorambucil {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Chlorambucil (Compound) resembles Melphalan (Compound)
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Melphalan (Compound)
Chlorambucil (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound)
Chlorambucil (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Melphalan (Compound)
Chlorambucil (Compound) causes Interstitial lung disease (Side Effect) and Interstitial lung disease (Side Effect) is caused by Melphalan (Compound)
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) resembles breast cancer (Disease) and breast cancer (Disease) is treated by Melphalan (Compound)
Chlorambucil (Compound) treats breast cancer (Disease) and breast cancer (Disease) resembles ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Melphalan (Compound)
Chlorambucil (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Melphalan (Compound)
Chlorambucil (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan
Chlorambucil (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Melphalan